Safety and efficacy of hemobeglogene autotemcel(hemo-cel) gene therapy in five patients with transfusion-dependent β-thalassemia
Molecular Therapy · 2026-05 · 34 (5) · 2611-2620
DOI: 10.1016/j.ymthe.2026.02.017 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Molecular Therapy, 2026-05. Verfasst von Sixi Liu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Shenzhen Children's Hospital, Shenzhen 518038, Guangdong, China. Electronic address: tiger647@126.com. Hauptthemen laut MEDLINE: beta-Thalassemia, Gene Therapy Agents, Genetic Therapy, Genetic Vectors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Shenzhen Science and Technology Innovation Program.
Abstract (Originalsprache)
Lentiviral vector-mediated hematopoietic stem cell gene therapy (HSC-GT) has emerged as a curative alternative to allogeneic transplantation for patients with transfusion-dependent β-thalassemia (TDT). However, challenges such as delayed platelet engraftment, variable transgene expression, and limited long-term safety data have hindered its broader implementation. Here, we report the safety and efficacy outcomes from a phase 1/2 clinical study evaluating hemobeglogene autotemcel (hemo-cel), an HSC-GT product developed with an optimized lentiviral vector encoding HBBT87Q and an improved manufacturing process. Five pediatric TDT patients, including three with β0/β0 genotypes, received hemo-cel and were followed for a median of 34.7 months. Hemo-cel infusion led to rapid neutrophil (median, day 18) and platelet (median, day 13) engraftment. No unexpected adverse events, clonal dominance, or replication-competent lentivirus were observed. All patients achieved transfusion independence for over 26 months (median, 34.3 months), with sustained HbAT87Q levels and vector copy numbers. Hemo-cel also contributed to iron overload control and supported normal growth in height and weight. These findings suggest that hemo-cel is a safe and effective option for TDT patients across diverse genotypes, including the most severe β0/β0.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Oncology, Shenzhen Children's Hospital, Shenzhen 518038, Guangdong, China. Electronic address: tiger647@126.com.
- BGI, Shenzhen 518083, China; BGI Hemogen therapeutic, Shenzhen 518083, China; BGI Research, Shenzhen 518083, China.
- Department of Hematology and Oncology, Shenzhen Children's Hospital, Shenzhen 518038, Guangdong, China.
- BGI, Shenzhen 518083, China; BGI Hemogen therapeutic, Shenzhen 518083, China.
- BGI, Shenzhen 518083, China; BGI Hemogen therapeutic, Shenzhen 518083, China; College of Life Sciences, University of Chinese Academy of Sciences, Beijing 100049, China.
- BGI, Shenzhen 518083, China; BGI Hemogen therapeutic, Shenzhen 518083, China. Electronic address: ouyangwenjie@genomics.cn.
Förderung
- Shenzhen Science and Technology Innovation Program
Zitieren
APA
Liu, S., Chen, Y., Li, Y., Qian, L., Dong, G., Zhang, Q., Zhou, X., Guo, H., Sun, H., Lin, Q., Yu, J., Zeng, X., Zou, H., He, J., Yao, W., Ouyang, W., & Liu, C. (2026). Safety and efficacy of hemobeglogene autotemcel(hemo-cel) gene therapy in five patients with transfusion-dependent β-thalassemia. Molecular Therapy, 34(5), 2611-2620. https://doi.org/10.1016/j.ymthe.2026.02.017
Vancouver
Liu S, Chen Y, Li Y, Qian L, Dong G, Zhang Q, et al. Safety and efficacy of hemobeglogene autotemcel(hemo-cel) gene therapy in five patients with transfusion-dependent β-thalassemia. Molecular Therapy. 2026;34(5):2611-2620. doi:10.1016/j.ymthe.2026.02.017
BibTeX
@article{Liu2026,
author = {Liu, Sixi and Chen, Yue and Li, Yue and Qian, Linxia and Dong, Guoyi and Zhang, Qian and Zhou, Xiaohui and Guo, Honglian and Sun, Haigang and Lin, Qihong and Yu, Jiaming and Zeng, Xinru and Zou, Huilin and He, Jiajun and Yao, Wenwen and Ouyang, Wenjie and Liu, Chao},
title = {Safety and efficacy of hemobeglogene autotemcel(hemo-cel) gene therapy in five patients with transfusion-dependent β-thalassemia},
journal = {Molecular Therapy},
year = {2026},
volume = {34},
number = {5},
pages = {2611--2620},
doi = {10.1016/j.ymthe.2026.02.017}
}
EUVIMED